Modra is committed to re-defining chemotherapy

As chemotherapy continues to be a cornerstone of cancer treatment for hundreds of thousands of patients worldwide, there remains considerable potential to improve its administration, minimize the severity of side effects, and limit the burden on patients and healthcare systems which arises from this commonly used form of therapy. 


Modra, which stands as a contraction of Modulated Oral Drug Absorption, aims to re-define chemotherapy by developing better taxanes that are less toxic, more effective and can be taken at home in tablet form. Our goal is to radically improve the therapeutic outcomes and everyday lives of the many cancer patients undergoing taxane chemotherapy today. 


Our lead program, ModraDoc006/r, is currently in Phase 2 clinical studies in prostate and breast cancer to further validate the value of the approach. 


The company, which was founded in June 2010 as a spin-off of the Netherland’s Cancer Institute (Nederlands Kanker Instituut Antoni van Leeuwenhoek) and MC Slotervaart Hospital in Amsterdam, is based in Amsterdam, the Netherlands.




Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more

Modra's Novel Approach

Boosted Oral Taxanes    
Learn more


Read more